Published by Global Banking & Finance Review®
Posted on February 11, 2026
1 min readLast updated: February 11, 2026
Add as preferred source on GoogleUS drug price regulations may lead to higher prices or delayed launches in Germany, warns Pharma Deutschland, urging government action.
FRANKFURT, Feb 11 (Reuters) - One of Germany's leading pharma industry lobby groups has warned that new drug price regulation in the United States could prompt companies to demand higher prices of new drugs in Germany or else shun a launch there.
In a statement on Wednesday, the Pharma Deutschland association, which counts 400 member companies, said that drugmakers active in both nations would have to re-evaluate their pricing and launch strategies.
As a result, "Germany could fall behind or miss out entirely when it comes to the introduction of new medicines", it added.
"Innovative medicines could be launched later or not at all in Germany or in Europe in order to avoid low price references and to protect pricing in the U.S." said Dorothee Brakmann, the lobby group's managing director.
She added the German government and the country's health system would have to respond to the challenge.
(Reporting by Ludwig Burger, Editing by Miranda Murray)
A pharmaceutical lobby is a group of organizations or individuals that advocate for the interests of the pharmaceutical industry, influencing legislation and public policy.
Pricing strategies can significantly affect drug launches, as companies may delay or avoid launching products in markets where prices are regulated or deemed too low.
Explore more articles in the Finance category
